Medication follow-up in patients after Covid-19 infection
Medication follow-up in patients after Covid-19 infection
DOI:
https://doi.org/10.47456/rbps.v24i4.39587Keywords:
Covid-19, Treatment, CardiovascularAbstract
Introduction:
Covid-19 is an infectious disease caused by the SARS-Cov-2 virus, which generates a severe acute respiratory syndrome, and which led to a current pandemic that started in 2020, with unprecedented morbidity and mortality. Despite everything that is known about the treatment of SARS-Cov-2 and the vaccines produced, there are still a high number of deaths due to issues that are not related to the vaccine, but mainly regarding cardiovascular events. Objectives: The objective of this research is to evaluate whether the drug treatment used is the correct one and the positive effect expected, demystifying the questions raised by the media about the beneficial effects of vaccines. Methods: This is a Systematic Review, for which 15 articles were selected from the U.S. National Library of Medicine and the National Institutes of Health (PubMed) and Virtual Health Library (BVS). Results: The publications demonstrated that the cardiovascular problems observed in patients with SARS-Cov-2 are due to the physiopathology of the disease and patients’ treatment, shifting the responsibility of vaccines for such feats. Conclusion: it is concluded that effective treatment must be instituted to avoid thromboembolism and ischemic events due to Covid-19 and vaccination must be incentivized.
Downloads
References
Arruda DE, Martins DD, Silva IF, Sousa MN. Prognóstico de pacientes com Covid-19 e doenças crônicas. Comun Ciênc Saúde [Internet]. 9 abr 2021 [citado 30 nov 2022];31(03):79-88.
Farkouh ME, Stone GW, Lala A, Bagiella E, Moreno PR, Nadkarni GN, et al. Anticoagulation in patients with Covid-19. J Am College Cardiol [Internet]. mar 2022 [citado 30 nov 2022];79(9):917-28.
Our World in Data [Internet]. Covid-19 data explorer; [citado 24 mar 2022]. Disponível em: https:// ourworldindata.org/explorers/coronavirus-data-explorer
Bezerra LA, Rodrigues JE, Souto HL, Nóbrega RA, Silva NS, Sousa MN. Atuação de uma equipe multiprofissional em tempos de Coronavírus. Rev interdisc saúde [Internet]. 17 set 2020 [citado 30 nov 2022];7(único):1993-2008.
World Health Organization (WHO) [Internet]. Coronavirus disease (Covid-19): How is it transmitted? [citado 24 mar 2022]. Disponível em: https://www.who. int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-how-is-it-transmitted
Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of Covid-19. Science [Internet]. 11 mar 2022 [citado 30 nov 2022];375(6585):1122-7.
World Health Organization (WHO) [Internet]. Clinical management of Covid-19. 27 mai 2020. Disponível em: https://www.who.int/teams/health-care-readiness/covid-19
Lee AR, Wong SY, Chai LY, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of Covid-19 vaccines in immune-compromised patients: systematic review and meta-analysis. BMJ [Internet]. 2 mar 2022 [citado 30 nov 2022]:e068632.
Al‐Ali D, Elshafeey A, Mushannen M, Kawas H, Shafiq A, Mhaimeed N, et al. Cardiovascular and hematological events post Covid‐19 vaccination: a systematic review. J Cell Molec Med [Internet]. 29 dez 2021 [citado 30 nov 2022];26(3):636-53.
Sampaio R, Mancini M. Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica. Rev Bras Fisiot [Internet]. Fev 2007 [citado 30 nov 2022];11(1):83-9.
Biblioteca Virtual em Saúde MS [Internet]. [citado 30 nov 2022]. Disponível em: https://bvsms.saude.gov.br/bvs/ ct/PDF/diretriz_do_grade.pdf
Falavigna M, Colpani V, Stein C, Azevedo LC, Bagattini AM, Brito GV, et al. Guidelines for the pharmacological treatment of Covid-19. The task force/consensus guideline of the Brazilian Association of Intensive Care Medicine, the Brazilian Society of Infectious Diseases and the Brazilian Society of Pulmonology and Tisiology. Rev Brasil Terap Intens [Internet]. 2020 [citado 30 nov 2022];32(2).
Kosiborod MN, Esterline R, Furtado RH, Oscarsson J, Gasparyan SB, Koch GG, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with Covid-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabet Endocrinol [Internet]. Set 2021 [citado 30 nov 2022];9(9):586-94.
Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with Covid-19 admitted to hospital: rapid randomised clinical trial. BMJ [Internet]. 14 out 2021 [citado 30 nov 2022]:n2400.
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. Efficacy and safety of Covid-19 convalescent plasma in hospitalized patients. JAMA Inter Med [Internet]. 1 fev 2022 [citado 30 nov 2022];182(2):115.
Bikdeli B, Talasaz AH, Sharif-Kashani B, Rashidi F, Taghi Beigmohammad MI, et al. Atorvastatin versus placebo in patients with Covid-19 in intensive care: randomized controlled trial. BMJ. 7 jan 2022;407(68):376.
Rodrigues C, Freitas-Santos RS, Levi JE, Senerchia AA, Lopes AT, Santos SR, et al. Hydroxychloroquine plus azithromycin early treatment of mild Covid-19 in outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance. Internat J Antimicrob Agents [Internet]. Ago 2021 [citado 30 nov 2022]:106428.
Buonfrate D, Chesini F, Martini D, Roncaglioni MC, Ojeda Fernandez ML, Alvisi MF, et al. High-dose ivermectin for early treatment of Covid-19 (cover study): a randomised, double-blind, multicenter, phase II, dose-finding, proof-of-concept clinical trial. Internat J Antimicrob Agents [Internet]. Fev 2022 [citado 30 nov 2022];59(2):106516.
Kharazmi AB, Moradi O, Haghighi M, Kouchek M, Manafi‐Rasi A, Raoufi M, et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe Covid‐19. Immun Inflam Disease [Internet]. 11 nov 2021 [citado 30 nov 2022];10(2):201-8.
Granfeldt A, Andersen LW, Vallentin MF, Hilberg O, Hasselstrøm JB, Sørensen LK, et al. Senicapoc treatment in Covid‐19 patients with severe respiratory insufficiency: a randomized, open‐Label, phase II trial. Acta Anaesthes Scand [Internet]. 11 abr 2022 [citado 30 nov 2022].
Sharma A, Elharram M, Afilalo J, Flannery A, Afilalo M, Tselios C, et al. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with Covid-19. Am Heart J [Internet]. Maio 2022 [citado 30 nov 2022];247:76-89.
Zdanyte M, Rath D. Cardiovascular risk assessment in Covid-19. Hämostaseo [Internet]. 11 ago 2021 [citado 30 nov 2022].
Kornowski R, Witberg G. Acute myocarditis caused by Covid-19 disease and following Covid-19 vaccination. Open Heart [Internet]. mar 2022 [citado 30 nov 2022];9(1):e001957.
Cryer MJ, Farhan S, Kaufmann CC, Jäger B, Garg A, Krishnan P, et al. Prothrombotic milieu, thrombotic events and prophylactic anticoagulation in hospitalized Covid-19 positive patients: a review. Clin Appl Thromb/Hemost [Internet]. Jan 2022 [citado 30 nov 2022];28:107602962210743.
Terentes-Printzios D, Gardikioti V, Solomou E, Emmanouil E, Gourgouli I, Xydis P, et al. The effect of an mRNA vaccine against Covid-19 on endothelial function and arterial stiffness. Hypertens Res [Internet]. 10 mar 2022 [citado 30 nov 2022];45(5):846-55.
Kantarcioglu B, Iqbal O, Walenga JM, Lewis B, Lewis J, Carter CA, et al. An update on the pathogenesis of Covid-19 and the reportedly rare thrombotic events following vaccination. Clin Appl Thromb/Hemost [Internet]. 1 jan 2021 [citado 30 nov 2022];27:107602962110214.
Cabezón Villalba G, Amat-Santos IJ, Dueñas C, Lopez OteromD, Catala P, Aparisi A, et al. Impact of the presence of heart disease, cardiovascular medications and cardiac events on outcome in Covid-19. Cardiol J [Internet]. 25 maio 2021 [citado 30 nov 2022];28(3):360-8.
Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with Covid-19. JAMA Internal Med [Internet]. 1 dez 2021 [citado 30 nov 2022];181(12):1612.
Florescu S, Stanciu D, Zaharia M, Kosa A, Codreanu D, Kidwai A, et al. Effect of antiplatelet therapy on survival and organ support-free days in critically Ill patients with Covid-19. JAMA [Internet]. 5 abr 2022 [citado 30 nov 2022];327(13):1247.
Ramacciotti E, Barile Agati L, Calderaro D, Aguiar VC, Spyropoulos AC, de Oliveira CC, et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalization for Covid-19 (Michelle): an open-label, multicenter, randomised, controlled trial. Lancet [Internet]. Jan 2022 [citado 30 nov 2022];399(10319):50- 9.
Pereira-Godoy JM, Russeff GJ, Cunha CH, Sato DY, Silva DF, Godoy HJ, et al. Increased prevalence of deep vein thrombosis and mortality in patients with Covid-19 at a referral center in Brazil. Phlebology J Venous Dis [Internet]. 8 set 2021 [citado 30 nov 2022]:026835552110419.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Brazilian Journal of Health Research
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
